Ron DePinho, Professor and Past President of MD Anderson Cancer Center, shared a post on LinkedIn about a recent article by Albert Ko et al, published in Annals of Internal Medicine:
“A rigorous new systematic review and meta-analysis in Annals of Internal Medicine synthesizing data from 48 randomized trials (~94,000 participants) provides reassuring evidence on a critical question: GLP-1 receptor agonists and dual agonists do not appear to increase cancer risk across multiple sites, including thyroid, pancreatic, breast, and kidney cancers.
While longer-term follow-up is still needed—particularly for rare or long-latency cancers—this work highlights the importance of grounding safety debates in high-quality randomized evidence as these agents are increasingly used for diabetes, obesity, and cardiometabolic disease.”
Title: Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis
Authors: Albert Ko, Yu-Cheng Chang, Furkan Bahar, Tsu Hsien Wang, Nutchapon Xanthavanij, Chun-Chiao Yu, Rebecca Jen-Ling Hsieh, Xin Ya See, Shao-Wei Lo, Junmin Song, Yuan Ping Hsia, Cho-Hung Chiang, Xiaocao Xu, Shuwen Lin, Cho-Han Chiang
Read the Full Article on Annals of Internal Medicine
More posts featuring Ron DePinho.